Subscribe to Newsletter
Business & Profession Business and Innovation, Professional Development

Business in Brief

  • Johnson & Johnson has completed its acquisition of Abbot Medical Optics, with the newly combined organization taking the brand name Johnson and Johnson Vision (J&J Vision).
  • Johnson & Johnson has completed its acquisition of Abbot Medical Optics, with the newly combined organization taking the brand name Johnson and Johnson Vision (J&J Vision).
  • L. Jay Katz, director of the glaucoma service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University, has been appointed chief medical officer of Glaukos.
  • Regenxbio has announced that the investigational new drug (IND) application for a Phase I trial of its wet AMD drug, RCX-314, is now active. Patient enrolment in the multicenter, open-label, multiple cohort dose escalation trial is expected to begin in Q2/Q3 of this year.
  • Shire has revealed revenue of $54 million from their dry eye drug, Xiidra (lifitegrast), which launched in the USA in August 2016. Shire also announced that it has filed a New Drug Submission (NDS) with Health Canada for the marketing authorization of lifitegrast for the treatment of dry eye in adults.
  • Carl Zeiss Meditec has received FDA approval of a Zeiss VisuMax software update, allowing US surgeons to perform SMILE for the correction of myopia.
  • Bausch + Lomb and Nicox have resubmitted a New Drug Application to the FDA for approval of latanoprostene bunod ophthalmic solution. If approved, the single-agent eyedrop for patients with glaucoma would be the first nitric-oxide donating prostaglandin F2α analog for ophthalmic use.
  • EyeGate has entered into a licensing agreement with Valeant to allow one of Valeant’s subsidiaries worldwide commercial and manufacturing rights to the candidate EGP-437 combination product for post-operative pain and inflammation in ocular surgery patients.
  • The Centers for Medicare and Medicaid Services (CMS) has announced that it will be providing up to $100 million of funding to improve education about the Quality Payment Program. The money will be awarded over the next five years to community-based organizations to provide training and educational resources on the program to small and rural practices across the USA.
  • According to a press release from Ocular Therapeutix, the FDA has accepted a new drug application resubmission for its dexamethasone insert, Dextenza.
Receive content, products, events as well as relevant industry updates from The Ophthalmologist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Ruth Steer
Related Product Profile
Uncover the Unique DNA of SPECTRALIS®

| Contributed by Heidelberg Engineering

Product Profiles

Access our product directory to see the latest products and services from our industry partners

Most Popular
Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine



The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: